InvestorsHub Logo
Followers 743
Posts 62179
Boards Moderated 11
Alias Born 10/05/2009

Re: Ecomike post# 1356

Monday, 03/02/2015 10:50:24 AM

Monday, March 02, 2015 10:50:24 AM

Post# of 2020
Kaboom $STLT NITE rasied the ask today from $3 to $17.50 smile

Make my day!!!!

Have you looked at STLT today? NITE raised the ask from $3 to $17.50 today, still no volume!!!!

KABOOM

Can I pcik them or what??? I have been the share buyer of STLT for a year now, LOL.

Also I missed this news I guess in Jan, or forgot it becasue there was no volume?

Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office; Crotoxin Administration for Cancer Treatment and Pain Relief
BY Market Wire
— 2:21 PM ET 01/15/2015

WEST DES MOINES, IA -- (Marketwired) -- 01/15/15 -- Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.

Cris Grunewald, President and CEO of Spotlight Innovation, stated, "We are creating and protecting value for Crotoxin as we progress through clinical efficacy trials. The legal protection afforded by the exclusivity of a U.S. patent is an important component of our commercialization strategy for Crotoxin, and a significant step in our value-building strategy for Celtic Biotech Iowa."

Dr. Paul Reid, President of Celtic Biotech Iowa, said, "Approval of this patent validates the tremendous amount of research and development that has gone into the development of Crotoxin by researchers around the world. We continue to focus our efforts on shepherding Crotoxin through clinical trials to commercial product, and building the foundation for a number of potential new therapies."

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies which have unique intellectual property (IP) in the medical sector. The Company utilizes relationships with the nation's leading academic and institutional IP developers to locate promising IP technologies with potential for market share capture. With our support, development resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We intend to partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at http://www.spotlightinnovation.com.

About Celtic Biotech Iowa Inc.
Celtic Biotech Iowa Inc., a subsidiary of Spotlight Innovation Inc., has developed novel, clinical trial-phase therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. Additional information available at http://www.celticbiotech.com.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.